Ignite Creation Date:
2024-05-06 @ 7:42 PM
Last Modification Date:
2024-10-26 @ 3:12 PM
Study NCT ID:
NCT06102005
Status:
RECRUITING
Last Update Posted:
2024-07-08
First Post:
2023-10-20
Brief Title:
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Parallel-group Dose Ranging Study to Assess the Efficacy Safety and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Moderate-to-severe Asthma
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AIRCULES
Brief Summary:
This is a Phase 2b global multicenter randomized double-blind placebo-controlled parallel group dose ranging study to assess the efficacy safety and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years inclusive with moderate-to-severe asthma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U1111-1280-5514 | OTHER | None | None |
| 2023-503712-33 | REGISTRY | CTIS | None |